<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D36E39A3-0BE7-4490-BE7A-A3C31DDC8CFD"><gtr:id>D36E39A3-0BE7-4490-BE7A-A3C31DDC8CFD</gtr:id><gtr:name>Perrigo</gtr:name><gtr:address><gtr:line1>Perrigo</gtr:line1><gtr:line2>Rosemont House</gtr:line2><gtr:line3>Yorkdale Industrial Estate</gtr:line3><gtr:postCode>LS11 9XE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/55DC1C6F-845B-49B8-9014-A7B749164AC1"><gtr:id>55DC1C6F-845B-49B8-9014-A7B749164AC1</gtr:id><gtr:name>Lariboisi?re Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516"><gtr:id>0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516</gtr:id><gtr:name>University Hospital Southampton NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Trust Management Offices Mailpoint 18, Tremona Road</gtr:line1><gtr:city>Southampton</gtr:city><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D36E39A3-0BE7-4490-BE7A-A3C31DDC8CFD"><gtr:id>D36E39A3-0BE7-4490-BE7A-A3C31DDC8CFD</gtr:id><gtr:name>Perrigo</gtr:name><gtr:address><gtr:line1>Perrigo</gtr:line1><gtr:line2>Rosemont House</gtr:line2><gtr:line3>Yorkdale Industrial Estate</gtr:line3><gtr:postCode>LS11 9XE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/55DC1C6F-845B-49B8-9014-A7B749164AC1"><gtr:id>55DC1C6F-845B-49B8-9014-A7B749164AC1</gtr:id><gtr:name>Lariboisi?re Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516"><gtr:id>0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516</gtr:id><gtr:name>University Hospital Southampton NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Trust Management Offices Mailpoint 18, Tremona Road</gtr:line1><gtr:city>Southampton</gtr:city><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/53196553-0949-4534-8A57-0627E996A16B"><gtr:id>53196553-0949-4534-8A57-0627E996A16B</gtr:id><gtr:firstName>Delphine</gtr:firstName><gtr:surname>Boche</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0501033"><gtr:id>D96CE9F1-8FF8-413A-9945-A72B856AF4BA</gtr:id><gtr:title>The mechanisms and consequences of plaque removal following Abeta immunotherapy in human Alzheimer's disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501033</gtr:grantReference><gtr:abstractText>Alzheimer?s disease (AD) is the commonest cause of dementia in old age. In AD a protein known as amyloid-beta (A?) accumulates in the brain regions critical for learning and memory.
Recently in animal studies immunization with A? has been shown to result in removal of A? from the brain associated with improvement in brain function. Some preliminary results of the initial human clinical trials suggested a slower cognitive deterioration in patients with an appropriate immune response.
The precise mechanism by which the activated immune system removes Ab is as yet unclear. Furthermore, some patients developed cerebral inflammatory complications, halting the clinical trials. Access to post mortem brain tissue from patients participating in the clinical trial of Ab immunotherapy puts us in a unique position to address important questions. We aim to clarify: (i) the mechanism(s) of Ab plaque removal (ii) if plaque removal can take place without the unwanted side effects of severe cerebral inflammation and (iii) the consequences of Ab removal on the other features of AD pathology.
This information is important in order to inform the second generation of trials of Ab immunotherapy which are already underway.</gtr:abstractText><gtr:technicalSummary>Immunization with amyloid beta-peptide (Abeta) has been proposed as a novel treatment for Alzheimer?s disease (AD). Experimental models and human clinical trials have shown that Abeta accumulation in the brain, a key feature of the disease, can be reversed by immunotherapy. However, the precise mechanism by which the activated immune system removes Abeta and the consequences this has on the brain are as yet unclear. Furthermore, some patients developed meningoencephalitis, halting the clinical trials. Access to post mortem brain tissue from patients in the first trial of Abeta immunotherapy puts me in a unique position to address important questions. I aim to clarify: (i) the mechanism of plaque removal (ii) whether plaque removal can take place without a severe and unacceptable meningoencephalitis and (iii) the consequences of Abeta removal on other features of AD pathology such as tau pathology, synaptic loss and cerebral amyloid angiopathy. Post-mortem brain tissues from 5 immunized patients are already available with their clinical data. Twenty additional immunized patients have given ante-mortem consent to post-mortem neuropathological examinations and 20 unimmunized AD controls from the Neuropathology archive, Southampton General Hospital, will be used as controls. The specific questions will be addressed using immunohistological techniques with sections of frontal and temporal lobes (usually severely affected in unimmunized AD). The midbrain will also be included in this study as a region relatively unaffected by Abeta pathology to assess whether the cerebral inflammation is localised to the vicinity of plaque-containing areas or whether it is a global event throughout the brain. In addition, within the immunized cases, areas devoid of plaques will be compared with areas containing residual plaques. All immunostaining will be assessed by computerized image analysis and multilabel confocal microscopy when appropriate. This information from the first human trl is important in order to inform the second generation of trials of Abeta immunotherapy in AD which are currently being planned or are already underway.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>236395</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Clinical Sciences Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Neuropathology</gtr:department><gtr:description>Prof Seth Love</gtr:description><gtr:id>40A6AEB8-C544-4C26-9B08-4EA13E080C80</gtr:id><gtr:impact>See publications</gtr:impact><gtr:partnerContribution>- Access to the South West Dementia Brain Bank
- Significant input into my research 
- Co-applicant on 3 grants.</gtr:partnerContribution><gtr:piContribution>- Access to the immunised AD cases</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lariboisi?re Hospital</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Alzheimer Centre</gtr:department><gtr:description>Dr Claire Paquet</gtr:description><gtr:id>341B3023-214C-4084-A828-604014713429</gtr:id><gtr:impact>- 2 papers under review, 1 paper in preparation
- Collaborator on the ARUK PhD scholarship</gtr:impact><gtr:partnerContribution>Scientific contribution on PKR a pro-apoptotic marker in chronic neurodegenerative diseases.</gtr:partnerContribution><gtr:piContribution>- Access to the immunised AD cases.
- Scientific and technical contribution.
- Collaborator on the grant ART-PhD2011-22</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lariboisi?re Hospital</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Alzheimer Centre</gtr:department><gtr:description>Prof Jacques Hugon</gtr:description><gtr:id>DF96E9B3-C718-46A7-B9C4-3067890267E8</gtr:id><gtr:impact>- 2 papers under review, 3 papers in preparation
- The outputs/outcomes are expected in 2015</gtr:impact><gtr:partnerContribution>Co-supervision of Mariko Taga, the ARUK scholarship student.</gtr:partnerContribution><gtr:piContribution>- Access to immunised AD cases
- We have been successful in obtaining funding to investigate whether a group of proteins (metaflammasome) known to be associated with the risk factors identified in AD (diabetes, hyperlipidaemia) are responsible for the chronic inflammation and thus the neuronal damage. This project is funded by the ARUK to support a PhD student.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Prof Clive Holmes</gtr:description><gtr:id>C24BB23E-44C1-4107-B909-AE0004DC56A3</gtr:id><gtr:impact>See publications</gtr:impact><gtr:partnerContribution>- Acted as the chief investigator for the clinical part of the study, performed the clinical assessment.
- Bring the clinical expertise essentiel to the work
- Co-applicant on other grants</gtr:partnerContribution><gtr:piContribution>- Involved in the clinico-neuropathological follow up of the AD patients actively immunised by Abeta42 (AN1792).
- co-applicant in the project to explore Systemic and central inflammation in Dementia with Lewy Bodies
- co-supervisor - Dr Jay Amin Clinical Fellow</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Perrigo</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:department>Elan Pharmaceuticals</gtr:department><gtr:description>Elan Pharmaceutical Ltd</gtr:description><gtr:id>2DC4F0C0-DEE5-4646-A04B-0E6EE7519279</gtr:id><gtr:impact>They have provided antibodies for our follow-up study. Publications: PMID: 18640458 PMID: 18953056</gtr:impact><gtr:partnerContribution>They initiated the clinical trial and provided trial data and antibodies for our follow-up study</gtr:partnerContribution><gtr:piContribution>Elan Pharmaceutical Company initiated the clinical trial and gave us access to phase I AN1791 treatment study data. We have attended meetings to present and share findings related to this study.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southampton University Hospitals NHS Trust (SUHT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Cellular Pathology</gtr:department><gtr:description>Prof James Nicoll</gtr:description><gtr:id>2536A8E9-9ED6-4880-BA2D-27DD7B4F82DA</gtr:id><gtr:impact>See all publications</gtr:impact><gtr:partnerContribution>- Bring the human neuropathology expertise, essentiel to the work
- Co-applicant on other grants
- Co-supervisor Mariko Taga (ART-PhD2011-22)</gtr:partnerContribution><gtr:piContribution>- Involved in the clinico-neuropathological follow-up of the AD patients actively immunised against Abeta42 (AN1792).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Prof James Nicoll</gtr:description><gtr:id>3947190C-56C0-4E4D-B920-C0ECD6F47124</gtr:id><gtr:impact>See all publications</gtr:impact><gtr:partnerContribution>- Bring the human neuropathology expertise, essentiel to the work
- Co-applicant on other grants
- Co-supervisor Mariko Taga (ART-PhD2011-22)</gtr:partnerContribution><gtr:piContribution>- Involved in the clinico-neuropathological follow-up of the AD patients actively immunised against Abeta42 (AN1792).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Alzheimer's Research UK Public event</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>91CF78C8-030B-41B8-8BEB-F0AD0DB8CA91</gtr:id><gtr:impact>The event included hands-on presentations by researchers who are using animal models of AD, as well as presentations by clinicians and academics within and outside the South Coast network. The interactive booths were particularly well received by the public.

Members of the public have requested to receive further information from upcoming events and the ARUK.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alzheimer's Society</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>538572EE-F5D1-47BD-8BFC-4503B8D56143</gtr:id><gtr:impact>To present the current treatments and research carry on at the University of Southampton on Alzheimer's disease and related dementias. 20 &amp;quot;lay&amp;quot; persons attended the meeting

This event has raised the awareness of the problems associated with dementia in terms of costs, care</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ARUK lab tour</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F2E2DC46-3F5D-40AA-8BA9-D5523BED19A4</gtr:id><gtr:impact>20 persons selected by the ARUK attended the lab tour.

One of the persons is funding our ARUK PhD scholarship.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alzheimer's Research UK Reception</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6CDF3EC3-3FA6-411E-BE20-CE3EA23E7CC6</gtr:id><gtr:impact>A joint presentation of Profs Clive Holmes and James Nicoll on the possibility of a vaccine for Alzheimer's disease. 50 parliamentarians

This presentation raised the awareness of the current clinical trials regarding Alzheimer's disease and preceded a series of parliamentary questions on dementia research.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neuroscience Information Day</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>090BAAD1-47DE-4390-A1F1-6FE73823EBB2</gtr:id><gtr:impact>The University of Southampton in conjunction with the Alzheimer's Society and the Alzheimer's Research Trust, highlighted the research into the condition that is being carried out within the University 60 &amp;quot;lay&amp;quot; persons attended the seminar

Over half of those who attending said they had come because they wanted help with understanding the illness, and subsequent feedback showed that over 98% of delegates felt that the conference had fulfilled their reason for attending.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GP meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AEA21EA9-64B8-415B-B119-AD0E89359CD9</gtr:id><gtr:impact>To present the current treatments on Alzheimer's disease 20 GPs

To update the GPs on current research and new treatment approaches on the Alzheimer's disease</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alzheimer's Research UK Westminster Reception</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D3CB9751-256F-4D40-B150-7EE2CCA49F42</gtr:id><gtr:impact>Around 70 persons including scientists, health professionals and members of the public attended the event.

This event has raised the awareness of the major challenge poses by dementia and the research strategy highlighted by ARUK.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>14000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>National Institutes of Health (US)</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>CA2EE342-1A2E-4DA3-9C3B-A3184B306522</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70254</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Gerald Kerkut Trust PhD</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>The Gerald Kerkut Charitable Trust</gtr:fundingOrg><gtr:id>87DD1DAC-CDAE-476E-95F1-ECF28F293EF1</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49996</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ART extension grant</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:fundingRef>ART/PG2006/4</gtr:fundingRef><gtr:id>B3B965E1-3E60-403B-B064-C56B6F6DA5A0</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Philippe Chatrier</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>Philippe Chatrier Foundation</gtr:fundingOrg><gtr:id>C183EEF9-0301-416B-BE84-210A7B146D0C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>316</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK major grant</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:fundingRef>ARUK-PG2012-8</gtr:fundingRef><gtr:id>60946FFC-8BB5-4ABB-A3BD-B7CE1A766AED</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>67310</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ART Major Research Grant</gtr:description><gtr:end>2010-08-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:fundingRef>ART/PG2006/4</gtr:fundingRef><gtr:id>BA3AB74F-7E96-4C06-B1DB-AAFA41C3D80A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>221606</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>FP7 people 2013 Marie Curie Intra European Fellowship</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Marie Curie Actions</gtr:fundingOrg><gtr:fundingRef>AlzProtAgeing n? 627152</gtr:fundingRef><gtr:id>28441C86-B149-46F5-B319-DFACF15E5505</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Forbes</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>928180C8-8E55-499A-9640-C3E414841300</gtr:id><gtr:impact>Financial analysis states that the huge financial losses by pharmaceutical companies in these failed trials could have been prevented if they had not ignored our findings (Sadeghi-Nejad N. The lessons of failure: what we can learn from Bapineuzumab's blow up. Forbes magazine 8/7/12)</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC Department of Health</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4B4D7D62-E2B7-4798-A2B9-1AE44C70C771</gtr:id><gtr:impact>Shaping Research policy on Dementia Research Strategy accross the UK</gtr:impact><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Recommendations from the US Alzheimer's Association to the NIH</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>22532BF4-398B-4826-9B23-6FC6107681AC</gtr:id><gtr:impact>The pathological &amp;quot;side effects&amp;quot; we have identified are relevant to current immunotherapy trials, indicating that at least in a proportion of patients removing amyloid from the brain has complications mainly related to changes in the cerebral vasculature (increased cerebral amyloid angiopathy) that need to be surmounted. 
Our advisory roles to the pharmaceutical industry have led to the inclusion of methods to monitor and interpret effects and side effects encountered in the current clinical trials.This led directly to a policy change by the US Food and Drug Administration in 2012 to implement advisory measures for the safe monitoring of patients receiving immunotherapy treatments for Alzheimer's (1). These recommendations include: reducing the dose of amyloid-modifying drugs in clinical participants who develop amyloid-related imaging abnormalities (ARIA), increasing the monitoring of study participants in Phase I and early Phase II studies to gain further knowledge about the mechanisms underlying micro haemorrhages, and updating reporting standards for MRIs used to evaluate and monitor for ARIA.

(1) USA Alzheimer's Association. Key Alzheimer drug development stakeholders join forces to establish clinical trial safeguards and accelerate discovery. http://www.alz.org/documents_custom/final_aria_news_release_071211_alz-dem_jrnl.pdf. Jul 2011.</gtr:impact><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Meeting with the Prime Minister</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F40311BA-0847-4894-A4CC-F97527857CE6</gtr:id><gtr:impact>Southampton's research programme has contributed to increasing UK government awareness about the importance of funding further research into Alzheimer's. The charity Alzheimer's Research Trust organised for the Southampton team to present their findings in the House of Lords, and at a face-to-face meeting with the then-Prime Minister Gordon Brown at 10 Downing Street in 2008. Both events were followed a year later by a ministerial summit on dementia on November 15, 2009 at which Prof Holmes chaired round table discussions. This meeting led to the formation of the ministerial advisory group on dementia research. Subsequently, in March 2012, Prime Minister David Cameron announced a doubling of funding for Alzheimer's disease to &amp;pound;66 million by 2015 and early detection screening.</gtr:impact><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lancet paper</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>E584F8F4-C5BA-404C-9392-CBE5C426E440</gtr:id><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Practitioners</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>73FA0AE4-751E-46BC-B1BC-D8263F1229BB</gtr:id><gtr:impact>Inform general practitioners on advance in new treatments for Alzheimer's disease</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Advise on Federal Drug Administration</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>F05C3AB4-8AF1-4140-B26F-53B21A7CFBB9</gtr:id><gtr:impact>A taskforce convened to advise the Federal Drug Administration on the design of early (pre-dementia) Alzheimer's disease studies, citesour research as evidence as to why it is necessary to start therapies before the onset of clinical dementia in order for it to have any positive effect. Report of the task force on designing clinical trials in early (predementia) AD.</gtr:impact><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The study has made use of cohort of AD patients actively immunised with Abeta42. The clinical follow-up and collection and assessment of post-mortem brain tissues was funded by the Alzheimer's Research Trust (Network Cooperation - ART/NPCG2003B)</gtr:description><gtr:id>5317D3C8-3308-45BF-831B-361EB7C75A48</gtr:id><gtr:impact>We are studying the pathological and clinical effects of the Abeta42 immunisation on the Alzheimer's disease (AD). Our findings are influencing the interpretation of the current generation of Abeta immunisation trials in AD. PMID 18640458</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Immunised AD brain tissues</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18640458</gtr:url><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FED6A18C-9EDB-4AAB-9862-F9DA7FD32231"><gtr:id>FED6A18C-9EDB-4AAB-9862-F9DA7FD32231</gtr:id><gtr:title>A? immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc2ef8836a5ad2175e2ae005784d6feb"><gtr:id>dc2ef8836a5ad2175e2ae005784d6feb</gtr:id><gtr:otherNames>Sakai K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/479B87AD-F151-4703-8300-631B6C707D1C"><gtr:id>479B87AD-F151-4703-8300-631B6C707D1C</gtr:id><gtr:title>Effect of active A? immunotherapy on neurons in human Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/213fb00b6dcea7c360c19c312f497623"><gtr:id>213fb00b6dcea7c360c19c312f497623</gtr:id><gtr:otherNames>Paquet C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/06FA8CFD-F63E-4F42-8CD4-FD32EF644E74"><gtr:id>06FA8CFD-F63E-4F42-8CD4-FD32EF644E74</gtr:id><gtr:title>Microglial alterations in human Alzheimer's disease following A?42 immunization.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4334f4bfe4552761ffd2f5b9bdc2ae7e"><gtr:id>4334f4bfe4552761ffd2f5b9bdc2ae7e</gtr:id><gtr:otherNames>Zotova E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C594F09E-2128-433A-A335-52B84C9709D0"><gtr:id>C594F09E-2128-433A-A335-52B84C9709D0</gtr:id><gtr:title>Are we getting to grips with Alzheimer's disease at last?</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52362efa5d0953623e76331524345fb2"><gtr:id>52362efa5d0953623e76331524345fb2</gtr:id><gtr:otherNames>Boche D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A8D07CF8-53BE-47CE-960D-D184F2F16235"><gtr:id>A8D07CF8-53BE-47CE-960D-D184F2F16235</gtr:id><gtr:title>Review: activation patterns of microglia and their identification in the human brain.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52362efa5d0953623e76331524345fb2"><gtr:id>52362efa5d0953623e76331524345fb2</gtr:id><gtr:otherNames>Boche D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6E0DD41D-01F1-4F23-BCC6-711F49B3143A"><gtr:id>6E0DD41D-01F1-4F23-BCC6-711F49B3143A</gtr:id><gtr:title>Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52362efa5d0953623e76331524345fb2"><gtr:id>52362efa5d0953623e76331524345fb2</gtr:id><gtr:otherNames>Boche D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/04E7916F-AAE7-4F6D-B039-7B83300AC001"><gtr:id>04E7916F-AAE7-4F6D-B039-7B83300AC001</gtr:id><gtr:title>Post-mortem analysis of neuroinflammatory changes in human Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Alzheimer's research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a53dde92aa730ee6da09a9b4e62f94ae"><gtr:id>a53dde92aa730ee6da09a9b4e62f94ae</gtr:id><gtr:otherNames>Gomez-Nicola D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CA7781CD-5D36-436E-8322-4064FC5FA7E4"><gtr:id>CA7781CD-5D36-436E-8322-4064FC5FA7E4</gtr:id><gtr:title>Inflammatory components in human Alzheimer's disease and after active amyloid-?42 immunization.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4334f4bfe4552761ffd2f5b9bdc2ae7e"><gtr:id>4334f4bfe4552761ffd2f5b9bdc2ae7e</gtr:id><gtr:otherNames>Zotova E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5CC032A0-1B5C-46B9-8F20-37D670B891BF"><gtr:id>5CC032A0-1B5C-46B9-8F20-37D670B891BF</gtr:id><gtr:title>Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/826529c33c68789b9df7c19ab1cfcc21"><gtr:id>826529c33c68789b9df7c19ab1cfcc21</gtr:id><gtr:otherNames>Weller RO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B2E45B67-3E6C-43B6-BA62-1A503DC63EAB"><gtr:id>B2E45B67-3E6C-43B6-BA62-1A503DC63EAB</gtr:id><gtr:title>Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52362efa5d0953623e76331524345fb2"><gtr:id>52362efa5d0953623e76331524345fb2</gtr:id><gtr:otherNames>Boche D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/509C5468-8F71-4CD5-A65C-BD5BDE693B40"><gtr:id>509C5468-8F71-4CD5-A65C-BD5BDE693B40</gtr:id><gtr:title>The role of the immune system in clearance of Abeta from the brain.</gtr:title><gtr:parentPublicationTitle>Brain pathology (Zurich, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52362efa5d0953623e76331524345fb2"><gtr:id>52362efa5d0953623e76331524345fb2</gtr:id><gtr:otherNames>Boche D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1015-6305</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BFC4A3C5-37A3-46D4-9B66-1C29295554D7"><gtr:id>BFC4A3C5-37A3-46D4-9B66-1C29295554D7</gtr:id><gtr:title>Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1f621ea49ff6712c7a8d2945dd4f86ef"><gtr:id>1f621ea49ff6712c7a8d2945dd4f86ef</gtr:id><gtr:otherNames>Holmes C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/90600323-82CF-46BC-8727-FF57E73B613E"><gtr:id>90600323-82CF-46BC-8727-FF57E73B613E</gtr:id><gtr:title>Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52362efa5d0953623e76331524345fb2"><gtr:id>52362efa5d0953623e76331524345fb2</gtr:id><gtr:otherNames>Boche D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4EF401A6-0830-4EDC-A38B-F0BF7ECC4F0A"><gtr:id>4EF401A6-0830-4EDC-A38B-F0BF7ECC4F0A</gtr:id><gtr:title>Investigating interventions in Alzheimer's disease with computer simulation models.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0253b8f8f15933e2f477106d06434b59"><gtr:id>0253b8f8f15933e2f477106d06434b59</gtr:id><gtr:otherNames>Proctor CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9FC7C1DA-9A0F-47B7-A8FF-00616A8E9350"><gtr:id>9FC7C1DA-9A0F-47B7-A8FF-00616A8E9350</gtr:id><gtr:title>Neuroinflammation in ageing and in neurodegenerative disease.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52362efa5d0953623e76331524345fb2"><gtr:id>52362efa5d0953623e76331524345fb2</gtr:id><gtr:otherNames>Boche D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB4D8C62-5BE4-43CC-B457-6D564FDEB6C1"><gtr:id>BB4D8C62-5BE4-43CC-B457-6D564FDEB6C1</gtr:id><gtr:title>Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.</gtr:title><gtr:parentPublicationTitle>Alzheimer's research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4334f4bfe4552761ffd2f5b9bdc2ae7e"><gtr:id>4334f4bfe4552761ffd2f5b9bdc2ae7e</gtr:id><gtr:otherNames>Zotova E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B2D7EBC6-B0B4-4E85-9477-AFDDF983CC29"><gtr:id>B2D7EBC6-B0B4-4E85-9477-AFDDF983CC29</gtr:id><gtr:title>Effect of amyloid-? (A?) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3?.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/108fd5c00070d6a0826962883d511c3a"><gtr:id>108fd5c00070d6a0826962883d511c3a</gtr:id><gtr:otherNames>Amin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501033</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>